Stem Cells (Dayton, Ohio)
John Wiley & Sons, Inc.
image
Advances in generating liver cells from pluripotent stem cells as a tool for modeling liver diseases
DOI 10.1002/stem.3154, Volume: 38, Issue: 5,
Abstract

Developing robust in vitro models of the liver is essential for studying the pathogenesis of liver diseases, hepatotoxicity testing, and regenerative medicine. Earlier studies were conducted using cell lines derived from hepatomas. Due to the inherent limitations of cell lines, researchers used primary human hepatocytes (PHHs), which are considered a gold standard for in vitro modeling of the liver. However, due to the high cost of PHHs and lack of donors, researchers have sought an alternative source for functional liver cells. Pluripotent stem cells (PSCs) emerged as a viable alternative due to their plasticity and high proliferative capacity. This review gives an overview of the major advances that have been achieved to develop protocols to generate liver cells such as hepatocytes, cholangiocytes, and Küpffer cells from PSCs. We also discuss their application in modeling the pathogenesis of liver diseases such as drug‐induced liver injury, acute liver failure, and hepatic steatosis.

Keywords
Maepa and Ndlovu: Advances in generating liver cells from pluripotent stem cells as a tool for modeling liver diseases

Significance statement

The liver is an essential organ in the body that performs crucial functions such as metabolism. Researchers have invested enormous resources to generate liver cells from induced pluripotent stem cells and to develop robust three‐dimensional liver organoids that faithfully resemble the liver. This study reviews in detail advances that have been achieved to develop protocols to generate hepatocytes, cholangiocytes, and Küpffer cells. It then discusses the application of these tools to model liver disease with a specific focus on hepatic steatosis, acute liver failure, and drug‐induced liver injury.

INTRODUCTION

The liver is a versatile and heterogeneous organ comprised of parenchymal cells (hepatocytes) and non‐parenchymal cells (NPCs) such as cholangiocytes, Küpffer cells (KCs), hepatic stellate cells, and liver endothelial cells. Hepatocytes are the major cell type in the liver occupying approximately 80%‐90% of the parenchymal mass of an adult organ.11, 22 Hepatocytes perform most of the essential functions in the liver. These include the synthesis of serum proteins such as albumin, detoxification of alcohol, drugs and other chemicals, and removal of inhaled poisons.33 These cells also play a key role in metabolism, storage of glycogen and lipids. Due to their importance in liver function, the pharmaceutical industry and researchers have invested huge resources to develop protocols to generate liver cells using pluripotent stem cells (PSCs) as a tool for modeling disease, toxicology studies, regenerative medicine, and gene therapy.22, 44, 55, 66, 77, 88 This review will describe in detail the recent advances made to generate hepatocytes, cholangiocytes, and KCs using PSCs. We will also discuss the future applications of three‐dimensional liver organoids in disease modeling and regenerative medicine.

GENERATION OF LIVER CELLS FROM PSCS

Hepatocyte‐like cells

Several studies have defined protocols for the generation of hepatocytes from PSCs11, 88, 99, 1010, 1111, 1212, 1313, 1414, 1515 and tissue‐resident progenitor cells.33, 1616, 1717 The protocols mimic key steps in ontogenic liver development, starting with commitment to definitive endoderm (DE), followed by generation of hepatoblasts, and finally specification to hepatocyte‐like cells (HLCs) using defined inductive and repressive signals (Figure 1). Generation of DE is achieved by culturing stem cells in the presence of Activin A, Wnt3a, bone morphogenic factor 4 (BMP4), fibroblast growth factor 2 (FGF2), and vascular endothelial growth factor (VEGF).11, 77, 1010, 1818, 1919 The resulting DE cells express Sox17, FOXA2, CXCR4, and CERBELUS1.1919 The transition from DE to hepatoblasts cells requires inductive signaling of BMP4 and FGF2, key signals required for liver bud formation in vivo, and repression of Activin.11, 77 The maturation of hepatoblasts to HLCs is achieved by culturing hepatoblasts in media supplemented with hepatic growth factor, oncostatin M, dexamethasone, and other growth factors essential for liver development and functional maturation.11, 77, 99, 1111, 1212, 2020, 2121 The resulting HLCs express key functional markers such as albumin, CYP3A4, and transcription factors like hepatocyte nuclear factor 4 alpha (HNF4α), HNF6, CEBPα, PROX1, and GATA4. Moreover, they have been shown to perform key hepatocyte functions including albumin secretion, glycogen synthesis, urea production, and LDL uptake.99, 1111, 1212, 1313, 2121 The major drawback associated with HLCs is that they retain some of the fetal characteristics like expression of alpha‐fetoprotein and limited expression of P450 enzymes compared to primary hepatocytes.22, 88

Generation of hepatocytes and cholangiocytes from human‐induced pluripotent stem cells. Hepatocytes were generated following key differentiation steps that involved induction of definitive endoderm (niche factors; RPMI‐B27, 100 ng/mL), Activin A (transforming growth factor‐β signaling family), and Wnt3A (Wnt signaling family), hepatoblasts using RPMI‐B27, hepatocyte growth factor, and subsequent lineage differentiation into hepatocytes in the presence of hepatocytes conditioned medium, Oncostatin M, and dexamethasone. Cholangiocytes are generated from hepatoblasts that are cultured in biliary differentiation medium supplemented with human growth hormone, interleukin 6, and sodium taurocholate hydrate
Figure 1
Generation of hepatocytes and cholangiocytes from human‐induced pluripotent stem cells. Hepatocytes were generated following key differentiation steps that involved induction of definitive endoderm (niche factors; RPMI‐B27, 100 ng/mL), Activin A (transforming growth factor‐β signaling family), and Wnt3A (Wnt signaling family), hepatoblasts using RPMI‐B27, hepatocyte growth factor, and subsequent lineage differentiation into hepatocytes in the presence of hepatocytes conditioned medium, Oncostatin M, and dexamethasone. Cholangiocytes are generated from hepatoblasts that are cultured in biliary differentiation medium supplemented with human growth hormone, interleukin 6, and sodium taurocholate hydrate

Several approaches have been taken to improve the functionality and maturation of hepatocytes. These include the use of vitamin C, 3D coculture, upregulation of c‐AMP22, 2222 and small molecules.22, 1212 A recent study by Ang and colleagues explored increasing the number of steps in the differentiation of PSC to hepatocytes, reasoning that the three‐step protocol does not faithfully mirror liver development in vivo .1010 They defined a roadmap for differentiation of stem cells to HLCs involving a transition through six consecutive lineage choices and identifying inductive and repressive signals at each juncture. Importantly, they demonstrated a temporally dynamic action of signals to specify one fate early during culturing, and subsequently repressing its formation later1010; thus, raising caution about the current protocols that heavily rely on providing the same signaling cues for a prolonged period of time. The roadmap involved generation of posterior foregut progenitors by exploiting the activation of retinoic acid, BMP, and FGF pathways while inhibiting transforming growth factor‐β (TGF‐β) signaling within 24 hours, and subsequently liver bud specification by activation of TGF‐β, BMP, and protein kinase A pathways and repression of Wnt pathway.1010 Finally, specification into HLCs was achieved by addition of Notch inhibitor (DAPT), TGF‐β inhibitor (A8301), Forskolin (FSK), and ascorbic acid 2‐phosphate (AAP). The resulting HLCs expressed all the phenotypic and functional hepatocyte markers, but still displayed limited expression of P450 enzymes compared to primary human hepatocytes (PHHs).1010

Zhang and colleagues developed a protocol to generate poster gut endoderm cells (PGECs) from stem cells by exploiting FGF, TGF, and Wnt signaling pathways.1919 PGECs were defined by the expression of CDX2 and could be expanded in the presence of epidermal growth factor (EGF), VEGF, Chir99021, and A8301. The expanded CDX2+ PGECs maintained chromosomal stability and were successfully transplanted into immunocompromised (NOD/SCID) mice without inducing teratomas.1919 Culturing CDX2+ PGECs in the presence of endothelial (human umbilical vein endothelial cells, HUVECs) and mesenchymal cells (mesenchymal stem cells, MSCs) generated functional liver bud organoids that rescued mice from acute liver failure (ALF),1919 demonstrating their potential utility in regenerative medicine.

A recent study demonstrated that PHHs can be efficiently converted into hepatic progenitor‐like cells (HepLCs) by exploiting relevant developmental cues such as the NAD+ ‐dependent deacetylase SIRT1 signaling.2323 This study further showed that expanded HepLCs can be converted into mature and metabolically functional HLCs using hepatic maturation medium.2323, 2424 Additionally, the 3D culture of HepLCs‐derived HLCs supported the infection and reactivation of Hepatitis B virus (HBV), demonstrating their potential utility as a model for studying HBV biology and antiviral therapy. Huch and colleagues have also developed a protocol for long‐term expansion of adult bile duct‐derived bipotent progenitor cells from human liver, showed that these cells initiated organoids formation and maintained genetic stability, a key consideration for generation of cells for regenerative medicine.33 Importantly, the ductal cells were differentiated into functional hepatocytes in vitro using a defined human differentiation medium and small molecules or in vivo upon transplantation.33

Studies have unveiled the culture and physical conditions required for the formation of 3D liver organoids.33, 1616, 2525 Huch and colleagues showed that long‐term expansion of 3D organoids can be achieved by culturing cells in the presence of the extracellular matrix (ECM) provided by Matrigel drops.33 However, a more recent study by Garnier and colleagues demonstrated that 3D organoids generated in Matrigel suspension exhibited high expression of differentiation markers and albumin expression compared to those embedded in Matrigel drop.2525 Therefore, these studies have highlighted a need to grow 3D organoids in an environment that replicates the tissue niche.

Cholangiocyte‐like cells

Cholangiocytes also known as biliary epithelial cells (BECs) are the main epithelial cells lining the intra‐ and extra‐hepatic ducts of the biliary tree.2626 These BECs primarily function to modify and transport bile constituents. The biliary excretion route is crucial for the removal of waste products in the body, such as excess cholesterol, bilirubin and hormones, as well as exogenous drugs and toxins from the liver. BECs are like hepatocytes, they have regenerative capacity to restore damaged bile ducts.2626 Several investigators have established protocols for generation of cholangiocytes from hiPSCs, hESCs, and HepRG cells.2727, 2828 Like hepatocytes, cholangiocytes are derived from hepatoblast (Figure 1), a common progenitor found in the liver bud during the early stages of liver organogenesis.2828, 2929, 3030 Dianat and colleagues successfully generated cholangiocytes‐like cells (CLCs) from hepatoblasts generated from hESCs and HepaRG cells that were cultured in defined media supplemented with growth hormones, EGF, interleukin 6 (IL‐6), and sodium taurocholate hydrate in the presence of ECM provided by collagen 1.2828 The resulting CLCs expressed cholangiocytes markers such as cytokeratin 18 (CK18), CK19, osteopontin (OPN), Secretin Receptor (SCTR), cystic fibrosis transmembrane conductance regulator (CFTR), apical sodium‐dependent bile acid transporter (ASBT), G‐protein‐coupled bile acid receptor (TGR5), VEGF receptor 2, and transcription factors Sox9, HNF6, and HNF1β.2828 The cells also formed functional cysts and bile ducts with apicobasal polarity.2828

A study by Sampaziotis has shown that cholangiocytes progenitors (CPs) can be matured by culturing cells in 3D to induce organoid formation.2929 Furthermore, modulating Notch signaling has been demonstrated to enhance the differentiation of CPs into mature cholangiocytes with similar characteristics as primary cells.2929, 3131 The cells cultured under these conditions proliferate rapidly, self‐organize into ring‐like structures, and give rise to cystic organoids and branched tubular structures bearing primary cilia.2929 Importantly, they expressed mature cholangiocytes markers such as ASBT, SCTR, CFTR, Somatostatin Receptor 2 (SSTR2), Aquaporin‐1 (AQP‐1), Anion Exchanger 2 (AE2), and Gamma‐Glutamyl Transferase (GGT).2929, 3131 In addition, the organoids displayed functional multidrug resistance protein‐1 (MDR1) activity by secreting rhodamine123, exported bile acid cholyl‐lysyl‐fluorescein, and responded to acetylcholine and VEGF stimulation.2929 It is worth noting that despite expressing signature markers of cholangiocytes and performing the key function of biliary cells, the cells still expressed fetal markers such as Sox9 as revealed by transcriptomic analysis.2929 Therefore, more research is still required to define the inductive signals and culture conditions that are required to drive the differentiation and maturation of cholangiocytes to resemble adult primary cells.

CLCs derived from patient tissues have been shown to faithfully recapitulate disease in vitro and validate drug efficacy. The drug octreotide was shown to reduce the size of organoids generated from hiPSCs derived from a patient with polycystic liver disease.2929 Moreover, CLCs generated from skin fibroblasts from a patient with a homozygous cystic fibrosis mutation displayed the key features of disease and failed to express functional CFTR.2929, 3131 The experimental drug VX809 increased the expression of CFTR and increased organoid size, validating the therapeutic effect of this drug for cystic fibrosis.2929

Küpffer cells

KCs are liver resident macrophages of monocyte origin. These cells form most of NPCs, representing approximately 15% of the total liver cells and 35% of the NPCs.11, 3232 KCs are specialized in performing scavenger and phagocytic functions.3333 KCs also play a role in maintaining liver homeostasis and contribute to the pathogenesis of different liver diseases including liver fibrosis, viral hepatitis, steatohepatitis, and drug‐induced liver injury (DILI).3333 KCs exert their effects by direct cell‐to‐cell contact or a paracrine mechanism involving the release of pro‐inflammatory cytokines such as tumor necrosis factor alpha (TNF‐α) and IL‐6, growth factors and reactive oxygen species (ROS).3434, 3535 These pro‐inflammatory mediators and ROS can cause injury to hepatocytes and NPCs.3535

Most studies that have included KCs in models of a liver have utilized cells of animal origin.3434, 3636, 3737 The use of human KCs in coculture studies with hepatocytes is impeded by donor availability, and low yield and/or purity of adult primary cells after tedious isolation procedures.3838 Additionally, once human primary KCs are isolated and purified, they lose functionality and fail to thrive in prolonged cultures.3939 Finally, the cost of purchasing human primary cells is a major barrier for the wide utilization in in vitro models. Hence, there is a need to develop robust protocols to generate mature KCs from stem cells.

A recent study by Tasnim and colleagues described a protocol for generating KCs using hiPSCs.3939 The protocol involved the differentiation of iPSC into pre‐macrophages using a modified protocol from Wilgenburg and colleagues.4040 iPSCs were cultured in mTeSR media supplemented with BMP‐4, VEGF, stem cell factor, and ROCK inhibitor to generate embryoid bodies (Figure 2). These cells expressed macrophage markers such as CD14, CD68, CD163, CD11, and CD32.3939 EBs were further cultured in X‐VIVO media supplemented with monocyte‐colony stimulating factor (M‐CSF), interleukin 3 (IL‐3), and β‐mercapto‐ethanol to create pre‐macrophages (Figure 2). Finally, pre‐macrophages were cultured in a mix of conditioned PHHs media and advanced DMEM to generate induced Küpffer cells (iKCs, Figure 2).3939 iKCs were found to exhibit similar morphology as primary human macrophages. Moreover, iKCs displayed a similar gene expression profile as primary macrophages as shown by microarray and quantitative RT‐PCR.3939 Interestingly, iKCs and pKC exhibited a transcriptomic profile that was distinct from bone marrow‐derived macrophages, alveolar macrophages, non‐liver macrophages as revealed by principal component analysis.3939 Finally, iKCs were able to perform phagocytosis, secrete cytokines, and be cocultured with hepatocytes similarly to primary KC.3939 It can be concluded that iPSCs‐derived KCs are like adult human primary KCs and they are mature and liver specific.3939 Therefore, iPSCs‐derived KCs and hepatocytes from the same donor could be used in coculture experiments and this will improve the outcomes resulting from mono‐hepatocytes cultures for modeling DILI, detection of hepatotoxicity, and modeling other liver diseases. Second, this will also provide a significant platform to enable investigators to perform genetic studies based on patient‐derived iKCs.

Stepwise generation of Küpffer cells from pluripotent stem cells. Pluripotent stem cells are cultured in the presence of niche factors (50 ng/mL bone morphogenic factor 4, 50 ng/mL vascular endothelial growth factor, 20 ng/mL, and 10 μM Rho‐associate protein kinase inhibitor) for 4 days, to generate embyroid bodies (EBs). Then, EBs were transferred into X‐VIVO media supplemented with 100 ng/mL monocyte‐colony stimulating factor, 25 ng/mL interleukin 3, 2 mM Glutamax, and 0.055 mM β‐mercaptoethanol to generate precursor macrophages. Precursor macrophages were then given hepatic cues and incubated in primary hepatocytes conditioned media and advanced DMEM plus supplements to generate induced Küpffer cells
Figure 2
Stepwise generation of Küpffer cells from pluripotent stem cells. Pluripotent stem cells are cultured in the presence of niche factors (50 ng/mL bone morphogenic factor 4, 50 ng/mL vascular endothelial growth factor, 20 ng/mL, and 10 μM Rho‐associate protein kinase inhibitor) for 4 days, to generate embyroid bodies (EBs). Then, EBs were transferred into X‐VIVO media supplemented with 100 ng/mL monocyte‐colony stimulating factor, 25 ng/mL interleukin 3, 2 mM Glutamax, and 0.055 mM β‐mercaptoethanol to generate precursor macrophages. Precursor macrophages were then given hepatic cues and incubated in primary hepatocytes conditioned media and advanced DMEM plus supplements to generate induced Küpffer cells

APPLICATION OF STEM CELL‐DERIVED ORGANOIDS IN MODELING LIVER DISEASE

Hepatotoxicity and drug‐induced liver injury

Hepatotoxicity is the second leading cause of drug failures in human beings, whereas DILI is a frequent cause of liver injury, accounting for approximately 50% of ALF cases.4141In vitro studies have revealed the potential of using PSCs‐derived HLCs to model DILI,4242 and immune‐mediated liver toxicity.3434 Additionally, several investigators have explored the potential use of PSCs‐derived HLCs for toxicity evaluation. For example, Takebe and colleagues generated a vascularized 3D liver buds resembling adult liver tissue, by coculturing three cell types (endoderm cells, HUVECs, and MSCs) in a 3D structure.88 These cells grew and aggregated into an organoid that mimicked a functional liver.88, 4343 Moreover, transplantation of the liver buds rescued recipient mice from drug‐induced liver failure.88 Another study demonstrated that in vitro liver organoids derived from hiPSCs exhibited comparable responses to those observed in PHH after treatment with acetaminophen.4444

A study by Godoy et al demonstrated that mono‐hepatocytes cultures have limited abilities of reproducing hepatotoxic effects observed in vivo .3232 Importantly, the toxic responses in vivo are mediated by a complex interplay between different cell types; therefore, the predictive performance of hepatocytes alone is limited. Following that, Kostanodiva and colleagues established a human and rat in vitro 3D liver coculture system containing both hepatocytes and NPCs.66 The resulting cells preserved the composition of hepatocytes, stellate cells, KCs, and endothelial cells and maintained liver function for a period of 3 months, as determined by albumin, fibrinogen, urea, and transferrin production.66 In addition, following incubation of the cells with drugs known to induce idiosyncratic toxicity, the 3D coculture model performed better than monolayer hepatocyte cultures in detecting hepatotoxicity.66

A study by Rose and colleagues assessed immune‐mediated hepatotoxicity over an extended period of time by coculturing rat donor‐matched primary hepatocytes with KCs.3434 Lipopolysaccharide activated hepatocyte and KC coculture performed better than hepatocyte monoculture in detecting trovafloxacin and acetaminophen induced immune‐mediated hepatotoxicity, indicated by decreased IL‐6 production with concomitant increase in Cyp3A4 activity.3434 A recent study by Tasnim and colleagues showed that hepatocytes‐iKCs coculture model was more sensitive at detecting hepatotoxicity induced by acetaminophen, trovafloxacin, and Chlorpromazine‐induced cholestasis when compared to hepatocytes alone.3939 These studies have unequivocally demonstrated that this model can provide a more stable and physiologically relevant platform for investigating drug‐induced and immune‐mediated adverse reactions that could lead to acute hepatotoxic effects.

Acute liver failure

Acute liver failure (ALF) is a rare but life‐threatening disease, caused by viral infections and DILI.4545 Patients suffering from ALF clinically present with hepatic dysfunction, abnormal liver biochemical metabolite values, and coagulopathy, followed by development of encephalopathy with multiple organ failure.4545 There are limited treatment options for these patients, with transplantation being the most preferred option. However, transplantation presents with its own challenges such as poor access to healthy livers, increased risk of death associated with transplantation of infected tissues, partial grafts, or grafts from donors without matching human leucocytes antigen.4646, 4747 This has led researchers to sought alternative sources of tissues or cells for transplantation. PHHs have been used for transplantation in patients with liver‐based metabolic disorders and ALF, and neonates and children with metabolic disorders.4848 This treatment option is limited by the shortage of donors with matching HLA.4949

The recent advances in generating 3D liver organoids from stem cells promises to provide an unlimited source of cells or tissues for liver engraftment. A recent study by Nie and colleagues successfully generated single‐donor human liver organoids (HLOs) using a 3D micro‐well system.4848 Transplantation of the organoids into renal capsule of ALF mice significantly improved survival.4848 Similarly, Takebe and colleagues showed that transplantation of liver buds rescued Alb‐Tk‐NOG mice from ALF.88 These studies have demonstrated the potential of organoid transplantation as a novel therapy for ALF.

Hepatic steatosis

Steatosis is a benign state of liver injury, defined by the presence of fat in the liver, which accounts for more than 5% of the total weight of the organ.5050, 5151 Non‐alcohol fatty liver disease (NAFLD) is a multifaceted and complicated disease characterized by steatosis. NAFLD patient may develop non‐alcoholic steatohepatosis (NASH), which can progress to liver fibrosis and cirrhosis.5151 Generally, NAFLD is caused by interactions between environmental and genetic factors. The precise pathogenesis of NAFLD and transition to NASH is not clearly understood, although the “two hit” model has been suggested as a possible mechanism.5252 The “first hit” is lipid accumulation followed by the “second hit” oxidative stress that increases the production of pro‐inflammatory cytokines and DNA damage.5252 Human liver models are required to elucidate the molecular and metabolic alteration involved in the progression of NAFLD.

More recently, a study by Ouchi and colleagues developed an in vitro model for steatohepatitis by incubating a multicellular HLO composed of HLCs, hepatic stellate‐like cells, and Küpffer‐like cells with free fatty acid (FFA) to induce steatosis and fibrosis.5353 The HLO displayed lipid accumulation in a dose dependent manner. Moreover, ELISA revealed that treating HLOs with FFA upregulated the secretion of IL‐6, TNF‐α, and IL‐8 compared to untreated HLOs.5353 Additionally, treating HLOs with FFA induced fibrosis as indicated by increased expression of P3PN, a known marker for enhanced fibrosis. Importantly, the authors also generated Wolman disease patient iPSC‐derived organoids and showed that the HLOs phenocopied the clinical features of disease. Finally, they demonstrated that treating patient‐derived HLOs with FGF19 improved survival of HLOs in culture, reduced lipid accumulation, reduced ROS production, and reduced stiffening of HLOs.5353 Therefore, this study provided a proof‐of‐concept for using 3D organoids for modeling NASH and screening of new therapeutic drugs for NASH.

CONCLUSION

Advances in the current protocols used to generate liver organoids hold a great promise for regenerative medicine and therapeutic applications. Researchers have been able to generate functional HLCs from PSCs11, 77, 88, 99, 1010, 1111, 1212, 1313, 1414, 2121 and patient‐derived tissues.33, 1616 Researchers have been able to expand and scale the production of cells,1919 and developed tools such as the Omni‐well array for mass production of liver buds.1414 Moreover, development of 3D liver organoids,1313, 2121 coculture of multiple lineages,88, 1616, 4848 and transplantation into immunocompromised mice88, 1414 have improved the maturity and functionality of HLCs. It is crucial that challenges associated with genomic instability and formation of teratomas after transplantation of iPSC‐derived liver cells are resolved to achieve wide‐scale clinical use in regenerative medicine and cell therapy. Finally, liver organoids developed from patient‐derived tissues have been shown to faithfully recapitulate disease in vitro and could be a useful tools to study disease pathogenesis and screening of novel therapeutic drugs.

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

S.W.M., H.N.: conception and design, manuscript writing; H.N.: financial support, administrative support, and final approval of manuscript.

ACKNOWLEDGMENTS

The authors would like to thank Jamie Pillaye, Stephanie Ncube, Caryn Rajh, and Veneshley Samuels for participating in discussions around the preparation of this manuscript. The work was supported by the National Research Foundation (NRF) Competitive Support for Unrated Researchers (CSUR, grant number 116260), NRF Incentive Support for Rated Researchers (IPRR, grant number 119071), and South African Medical Research Council Capacity Development Grant to H.N. S.W.M. PhD fellowship was funded through a NRF grant holder‐linked fellowship from H.N.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

REFERENCES

1 

Si‐TayebK, NotoFK, NagaokaM, et al. . Highly efficient generation of human hepatocyte‐like cells from induced pluripotent stem cells. Hepatology. 2010;51(1):, pp.297‐305. , doi: 10.1002/hep.23354.

2 

YiangouL, RossADB, GohKJ, VallierL. . Human pluripotent stem cell‐derived endoderm for modeling development and clinical applications. Cell Stem Cell. 2018;22(4):, pp.485‐499. , doi: 10.1016/J.STEM.2018.03.016.

3 

HuchM, GehartH, van BoxtelR, et al. . Long‐term culture of genome‐stable bipotent stem cells from adult human liver. Cell. 2015;160(1–2):, pp.299‐312. , doi: 10.1016/J.CELL.2014.11.050.

4 

GoldringC, AntoineDJ, BonnerF, et al. . Stem cell‐derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury. Hepatology. 2017;65(2):, pp.710‐721. , doi: 10.1002/hep.28886.

5 

HuchM, DorrellC, BojSF, et al. . In vitro expansion of single Lgr5+ liver stem cells induced by Wnt‐driven regeneration. Nature. 2013;494(7436):, pp.247‐250. , doi: 10.1038/nature11826.

6 

KostadinovaR, BoessF, ApplegateD, et al. . A long‐term three dimensional liver co‐culture system for improved prediction of clinically relevant drug‐induced hepatotoxicity. Toxicol Appl Pharmacol. 2013;268(1):, pp.1‐16. , doi: 10.1016/J.TAAP.2013.01.012.

7 

RashidST, CorbineauS, HannanN, et al. . Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010;120(9):, pp.3127‐3136. , doi: 10.1172/JCI43122.

8 

TakebeT, SekineK, EnomuraM, et al. . Vascularized and functional human liver from an iPSC‐derived organ bud transplant. Nature. 2013;499(7459):, pp.481‐484. , doi: 10.1038/nature12271.

9 

SongZ, CaiJ, LiuY, et al. . Efficient generation of hepatocyte‐like cells from human induced pluripotent stem cells. Cell Res. 2009;19(11):, pp.1233‐1242. , doi: 10.1038/cr.2009.107.

10 

AngLT, TanAKY, AutioMI, et al. . A roadmap for human liver differentiation from pluripotent stem cells. Cell Rep. 2018;22(8):, pp.2190‐2205. , doi: 10.1016/j.celrep.2018.01.087.

11 

ChenY‐F, TsengC‐Y, WangH‐W, KuoH‐C, YangVW, LeeOK. . Rapid generation of mature hepatocyte‐like cells from human induced pluripotent stem cells by an efficient three‐step protocol. Hepatology. 2012;55(4):, pp.1193‐1203. , doi: 10.1002/hep.24790.

12 

SillerR, GreenhoughS, NaumovskaE, SullivanGJ. . Small‐molecule‐driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Rep. 2015;4(5):, pp.939‐952. , doi: 10.1016/J.STEMCR.2015.04.001.

13 

SullivanGJ, HayDC, ParkI‐H, et al. . Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology. 2010;51(1):, pp.329‐335. , doi: 10.1002/hep.23335.

14 

TakebeT, SekineK, KimuraM, et al. . Massive and reproducible production of liver buds entirely from human pluripotent stem cells. Cell Rep. 2017;21(10):, pp.2661‐2670. , doi: 10.1016/J.CELREP.2017.11.005.

15 

TouboulT, HannanNRF, CorbineauS, et al. . Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology. 2010;51(5):, pp.1754‐1765. , doi: 10.1002/hep.23506.

16 

BroutierL, Andersson‐RolfA, HindleyCJ, et al. . Culture and establishment of self‐renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11(9):, pp.1724‐1743. , doi: 10.1038/nprot.2016.097.

17 

KruitwagenHS, OosterhoffLA, VernooijIGWH, et al. . Long‐term adult feline liver organoid cultures for disease modeling of hepatic steatosis. Stem Cell Rep. 2017;8(4):, pp.822‐830. , doi: 10.1016/J.STEMCR.2017.02.015.

18 

Gouon‐EvansV, BoussemartL, GadueP, et al. . BMP‐4 is required for hepatic specification of mouse embryonic stem cell‐derived definitive endoderm. Nat Biotechnol. 2006;24(11):, pp.1402.

19 

ZhangR‐R, KoidoM, TadokoroT, et al. . Human iPSC‐derived posterior gut progenitors are expandable and capable of forming gut and liver organoids. Stem Cell Rep. 2018;10(3):, pp.780‐793. , doi: 10.1016/J.STEMCR.2018.01.006.

20 

HannanNRF, SegeritzC‐P, TouboulT, VallierL. . Production of hepatocyte‐like cells from human pluripotent stem cells. Nat Protoc. 2013;8(2):, pp.430‐437. , doi: 10.1038/nprot.2012.153.

21 

AgarwalS, HoltonKL, LanzaR. . Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells. 2008;26(5):, pp.1117‐1127. , doi: 10.1634/stemcells.2007-1102.

22 

TakebeT, ZhangR‐R, KoikeH, et al. . Generation of a vascularized and functional human liver from an iPSC‐derived organ bud transplant. Nat Protoc. 2014;9(2):, pp.396‐409. , doi: 10.1038/nprot.2014.020.

23 

FuGB, HuangWJ, ZengM, et al. . Expansion and differentiation of human hepatocyte‐derived liver progenitor‐like cells and their use for the study of hepatotropic pathogens. Cell Res. 2019;29(1):, pp.8‐22. , doi: 10.1038/s41422-018-0103-x.

24 

WuF, WuD, RenY, et al. . Generation of hepatobiliary organoids from human induced pluripotent stem cells. J Hepatol. 2019;70(6):, pp.1145‐1158. , doi: 10.1016/j.jhep.2018.12.028.

25 

GarnierD, LiR, DelbosF, et al. . Expansion of human primary hepatocytes in vitro through their amplification as liver progenitors in a 3D organoid system. Sci Rep. 2018;8(1):8222, doi: 10.1038/s41598-018-26584-1.

26 

TabibianJH, MasyukAI, MasyukTV, O'HaraSP, LaRussoNF. Physiology of cholangiocytesComprehensive Physiology. Vol 3Hoboken, NJ: John Wiley & Sons, Inc.; 2013:, pp.541‐565. , doi: 10.1002/cphy.c120019.

27 

BoulterL, GovaereO, BirdTG, et al. . Macrophage‐derived Wnt opposes notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med. 2012;18(4):, pp.572‐579. , doi: 10.1038/nm.2667.

28 

DianatN, Dubois‐Pot‐SchneiderH, SteichenC, et al. . Generation of functional cholangiocyte‐like cells from human pluripotent stem cells and HepaRG cells. Hepatology. 2014;60(2):, pp.700‐714. , doi: 10.1002/hep.27165.

29 

SampaziotisF, Cardoso de BritoM, MadrigalP, et al. . Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol. 2015;33(8):, pp.845‐852. , doi: 10.1038/nbt.3275.

30 

ShanJ, SchwartzRE, RossNT, et al. . Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol. 2013;9(8):, pp.514‐520. , doi: 10.1038/nchembio.1270.

31 

OgawaM, OgawaS, BearCE, et al. . Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat Biotechnol. 2015;33(8):, pp.853‐861. , doi: 10.1038/nbt.3294.

32 

GodoyP, HewittNJ, AlbrechtU, et al. . Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non‐parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87(8):, pp.1315‐1530. , doi: 10.1007/s00204-013-1078-5.

33 

BilzerM, RoggelF, GerbesAL. . Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26(10):, pp.1175‐1186. , doi: 10.1111/j.1478-3231.2006.01342.x.

34 

RoseKA, HolmanNS, GreenAM, AndersonME, LELC. . Co‐culture of hepatocytes and Kupffer cells as an in vitro model of inflammation and drug‐induced hepatotoxicity. J Pharm Sci. 2017;105(2):, pp.950‐964. , doi: 10.1016/S0022-3549(15)00192-6.Co-culture.

35 

PfeifferE, KegelV, ZeilingerK, et al. . Featured article: isolation, characterization, and cultivation of human hepatocytes and non‐parenchymal liver cells. Exp Biol Med. 2015;240(5):, pp.645‐656. , doi: 10.1177/1535370214558025.

36 

TukovFF, MaddoxJF, AmacherDE, BobrowskiWF, RothRA, GaneyPE. . Modeling inflammation–drug interactions in vitro: a rat Kupffer cell‐hepatocyte coculture system. Toxicol In Vitro. 2006;20(8):, pp.1488‐1499. , doi: 10.1016/J.TIV.2006.04.005.

37 

ZinchenkoYS, SchrumLW, ClemensM, CogerRN. . Hepatocyte and Kupffer cells co‐cultured on micropatterned surfaces to optimize hepatocyte function. Tissue Eng. 2006;12(4):, pp.751‐761. , doi: 10.1089/ten.2006.12.751.

39 

TasnimF, XingJ, HuangX, et al. . Generation of mature Kupffer cells from human induced pluripotent stem cells. Biomaterials. 2019;192:, pp.377‐391. , doi: 10.1016/J.BIOMATERIALS.2018.11.016.

40 

van WilgenburgB, BrowneC, VowlesJ, CowleySA. . Efficient, long term production of monocyte‐derived macrophages from human pluripotent stem cells under partly‐defined and fully‐defined conditions. PLoS One. 2013;8(8):e71098, doi: 10.1371/journal.pone.0071098.

41 

MedineCN, Lucendo‐VillarinB, StorckC, et al. . Developing high‐fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med. 2013;2(7):, pp.505‐509. , doi: 10.5966/sctm.2012-0138.

42 

AviorY, LevyG, ZimermanM, et al. . Microbial‐derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells–derived and fetal hepatocytes. Hepatology. 2015;62(1):, pp.265‐278. , doi: 10.1002/HEP.27803@10.1002/(ISSN)1527-3350(CAT)VIRTUALISSUES(VI)HEPATOLOGYHONORROLEEDITORSCHOICE.

43 

CampJG, SekineK, GerberT, et al. . Multilineage communication regulates human liver bud development from pluripotency. Nature. 2017;546(7659):, pp.533‐538. , doi: 10.1038/nature22796.

44 

SgoddaM, DaiZ, ZweigerdtR, SharmaAD, OttM, CantzT. . A scalable approach for the generation of human pluripotent stem cell‐derived hepatic organoids with sensitive hepatotoxicity features. Stem Cells Dev. 2017;26(20):, pp.1490‐1504. , doi: 10.1089/scd.2017.0023.

45 

BernalW, WendonJ. . Acute liver failure. N Engl J Med. 2013;369(26):, pp.2525‐2534. , doi: 10.1056/NEJMra1208937.

46 

BernalW, CrossTJS, AuzingerG, et al. . Outcome after wait‐listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol. 2009;50(2):, pp.306‐313. , doi: 10.1016/J.JHEP.2008.09.012.

47 

GermaniG, TheocharidouE, AdamR, et al. . Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol. 2012;57(2):, pp.288‐296. , doi: 10.1016/j.jhep.2012.03.017.

48 

NieY‐Z, ZhengY‐W, OgawaM, MiyagiE, TaniguchiH. . Human liver organoids generated with single donor‐derived multiple cells rescue mice from acute liver failure. Stem Cell Res Ther. 2018;9(1):5, doi: 10.1186/s13287-017-0749-1.

49 

FoxIJ, ChowdhuryJR. . Hepatocyte transplantation. Am J Transplant. 2004;4(Supp.6):, pp.7‐13. , doi: 10.1111/j.1600-6135.2004.0340.x.

50 

BruntEM, WongVW‐S, NobiliV, et al. . Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1(1):15080, doi: 10.1038/nrdp.2015.80.

51 

YounossiZM, KoenigAB, AbdelatifD, FazelY, HenryL, WymerM. . Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):, pp.73‐84. , doi: 10.1002/hep.28431.

52 

TilgH, MoschenAR. . Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):, pp.1836‐1846. , doi: 10.1002/hep.24001.

53 

OuchiR, TogoS, KimuraM, et al. . Modeling steatohepatitis in humans with pluripotent stem cell‐derived organoids. Cell Metab. 2019;30(2):, pp.374‐384.e6. , doi: 10.1016/J.CMET.2019.05.007.

https://www.researchpad.co/tools/openurl?pubtype=article&doi=10.1002/stem.3154&title=Advances in generating liver cells from pluripotent stem cells as a tool for modeling liver diseases&author=Setjie W. Maepa,Hlumani Ndlovu,&keyword=cholangiocytes,hepatocytes,Küpffer cells,liver,liver diseases,pluripotent stem cells,&subject=Concise Review,Concise Reviews,